|
|
 |
|
Viewing report
|
|
|
|
U.S. Lipid Regulators Markets
Frost & Sullivan, June 2002
Low Awareness Limits Market Potential
While drugs that can lower cholesterol and reduce the risk of cardiovascular disease by reducing lipid levels have been on the market for over three decades, a sizable portion of the dyslipidemic population remains untreated. Thus, major pharmaceutical companies need to aggressively pursue physician awareness initiatives and direct-to-consumer campaigns to bridge the gap. This Frost & Sullivan study analyzes the U.S. markets for lipid regulators, including a full range of statin and non-statin products. It tracks changes in demand and the development of new products. With its discussion of key industry challenges and presentation of expert revenue forecasts, this study offers your firm an essential guide to the future of the field.
Generics, New Combination Therapies Threaten Established Products
The loss of patent exclusivity for lipid reducers will lead to the introduction of low-cost generics, says the study’s author. Although generics will benefit patients, they will also constrain market revenues for branded products. Competition will intensify in statin markets in the medium term, when the patents for two major brands expire.
At the same time, newer, more potent lipid-lowering agents could usurp market share from incumbent brands. The development of combination
lipid-lowering agents could cannibalize the market and pose a challenge to sustaining growth trends, states the analyst. By evaluating the threat from generics and assessing the impact of new products on the marketplace, this study will enable your company to target the most lucrative areas.
New Clinical Trials Should Spark Interest in Lipid Regulators
A number of large clinical trials have recently demonstrated the benefits associated with improving the lipid profile, says the author. These studies have established the role of statins in correcting dyslipidemia and reversing coronary heart disease. Because most physicians base prescription decisions on the results of large clinical trials, doctors who are aware of statins are gaining confidence in their use.
Meanwhile, the publication of guidelines by influential healthcare organizations that advocate aggressive management of dyslipidemia should inspire more doctors to investigate and prescribe lipid-reducing products. This study, which identifies market drivers and restraints, will help your firm prepare for the challenges and opportunities that lie ahead.
|
|
|
|
